Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Boris E Acevedo"'
Publikováno v:
Biotecnología Aplicada, Vol 33, Iss 3, Pp 3301-3307 (2016)
Externí odkaz:
https://doaj.org/article/f0f0ae34ff674f85b47ef30d26766483
Autor:
Yanelys Morera, Mónica Bequet, Marta Ayala, Jorge V Gavilondo, Jorge Castro, Pedro Puente, Julio Ancízar, José Suarez, Javier Sanchez, Karelia Cosme, Dania Bacardí, Boris E Acevedo
Publikováno v:
Biotecnología Aplicada, Vol 29, Iss 2, Pp 118-121
CIGB-247 is a novel cancer therapeutic vaccine that uses a mutated form of human vascular endothelial growth factor (VEGF) as antigen in combination with the oil-free adjuvant VSSP (very small sized proteoliposomes of Neisseria meningitidis outer mem
Externí odkaz:
https://doaj.org/article/112aa2f7c1824ec9a6d1da43bbe64aa2
Autor:
Mónica Bequet-Romero, Yanelys Morera, Marta Ayala, Boris E Acevedo, Humberto Lamdan, Jorge V Gavilondo
Publikováno v:
Biotecnología Aplicada, Vol 26, Iss 1, Pp 80-83
Externí odkaz:
https://doaj.org/article/f2614477004b4e7e9b6d38d97b06691b
Autor:
Silvio E. Perea, Daniel F. Alonso, Boris E. Acevedo, Roberto E. Gómez, Lila Castellanos, Fernando Benavent, Arielis Rodriguez, Jeovanis Gil, Hernán G. Farina, Yasser Perera
CIGB-300, formerly known as P15-tat, is a proapoptotic peptide with established antiproliferative activity in vitro and antitumoral activity in vivo. This hypothesis-driven peptide was initially selected for its ability to impair the in vitro CK2-med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::960b87302575a8d384ca531ada00ca47
https://doi.org/10.1158/1535-7163.c.6531758.v1
https://doi.org/10.1158/1535-7163.c.6531758.v1
Autor:
Jorge, Berlanga, José I, Fernández, Ernesto, López, Pedro A, López, Amaurys, del Río, Carmen, Valenzuela, Julio, Baldomero, Verena, Muzio, Manuel, Raíces, Ricardo, Silva, Boris E, Acevedo, Luis, Herrera
Publikováno v:
MEDICC review. 15(1)
Diabetic foot ulcer is a principal diabetic complication. It has been shown that diabetic patients have decreased growth factor concentrations in their tissues, particularly epidermal growth factor. Growth factor shortage impairs wound healing, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c259dff69d84e2037693582268e8de5
https://pubmed.ncbi.nlm.nih.gov/23396236
https://pubmed.ncbi.nlm.nih.gov/23396236
Autor:
Yasser, Perera, Heydi C, Costales, Yakelin, Diaz, Osvaldo, Reyes, Hernan G, Farina, Lissandra, Mendez, Roberto E, Gómez, Boris E, Acevedo, Daniel E, Gomez, Daniel F, Alonso, Silvio E, Perea
Publikováno v:
Journal of peptide science : an official publication of the European Peptide Society. 18(4)
CIGB-300 is a novel anticancer peptide that impairs the casein kinase 2-mediated phosphorylation by direct binding to the conserved phosphoacceptor site on their substrates. Previous findings indicated that CIGB-300 inhibits tumor cell proliferation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4e903f6d595622659113b032ab870873
https://pubmed.ncbi.nlm.nih.gov/22407768
https://pubmed.ncbi.nlm.nih.gov/22407768
Autor:
Arielis RodriÌguez-Ulloa, Yassel Ramos, Jeovanis Gil, Yasser Perera, Lila Castellanos-Serra, Yairet GarciÌa, LaÌzaro Betancourt, Vladimir Besada, Luis J. GonzaÌlez, Jorge FernaÌndez-de-Cossio, Aniel Sanchez, Joem M. Serrano, HernaÌn Farina, Daniel F. Alonso, Boris E. Acevedo, Gabriel PadroÌn, Alexis Musacchio, Silvio E. Perea
Publikováno v:
Journal of Proteome Research; Oct2010, Vol. 9 Issue 10, p5473-5483, 11p